Fidelis Research

Executive Summary

Fidelis Research is a specialized contract research organization (CRO) and biospecimen provider headquartered in London, with a strategic focus on high-quality human biological specimen procurement. The company also offers clinical research site management and patient support programs, leveraging a network of clinical sites primarily in Eastern and Southeastern Europe. Founded in 2020, Fidelis Research operates in the AI/Machine Learning and Drug Delivery sectors, though its core activities are centered on specimen logistics and site management. The company's stage is listed as 'Approved,' indicating it has passed initial vetting on platforms like BiopharmGuy. As a relatively young CRO, Fidelis Research is positioned to capitalize on the growing demand for outsourced clinical services and diverse biospecimen sources, particularly from emerging European markets. Its success hinges on expanding its site network, securing repeat contracts from pharmaceutical sponsors, and maintaining high specimen quality standards.

Upcoming Catalysts (preview)

• Q4 2026Major Contract Win with Top Pharma Sponsor40% success
• Q2 2027Expansion of Clinical Site Network into Western Europe30% success
• Q3 2026Regulatory Accreditation for Biospecimen Services50% success